Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Shares Shorted: Short Interest Up 104.5% in September

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) was the recipient of a significant increase in short interest during the month of September. As of September 30th, there was short interest totaling 98,600 shares, an increase of 104.5% from the September 15th total of 48,204 shares. Currently, 0.6% of the company’s stock are sold short. Based on an average daily trading volume, of 611,232 shares, the days-to-cover ratio is currently 0.2 days.

Enlivex Therapeutics Stock Up 2.0%

Shares of NASDAQ:ENLV traded up $0.00 on Thursday, reaching $0.22. 377,376 shares of the company’s stock were exchanged, compared to its average volume of 356,896. The business’s 50-day moving average is $1.03 and its two-hundred day moving average is $6.70. Enlivex Therapeutics has a fifty-two week low of $0.21 and a fifty-two week high of $27.15. The firm has a market capitalization of $3.85 million, a price-to-earnings ratio of -0.03 and a beta of 1.42.

Institutional Investors Weigh In On Enlivex Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Bank of America Corp DE boosted its stake in Enlivex Therapeutics by 53.2% in the first quarter. Bank of America Corp DE now owns 130,401 shares of the company’s stock valued at $121,000 after acquiring an additional 45,303 shares during the period. WINTON GROUP Ltd bought a new position in shares of Enlivex Therapeutics during the second quarter valued at approximately $55,000. Finally, Susquehanna International Group LLP raised its position in shares of Enlivex Therapeutics by 1,428.5% during the 2nd quarter. Susquehanna International Group LLP now owns 157,648 shares of the company’s stock worth $87,000 after purchasing an additional 147,334 shares during the period. Institutional investors and hedge funds own 1.02% of the company’s stock.

Analyst Ratings Changes

ENLV has been the topic of a number of research analyst reports. Zacks Research downgraded Enlivex Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, October 2nd. Wall Street Zen upgraded Enlivex Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 29th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Enlivex Therapeutics in a report on Tuesday, September 22nd. One investment analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Enlivex Therapeutics presently has an average rating of “Hold” and an average price target of $247.50.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics Ltd. is a clinical-stage biotechnology company developing immunotherapies designed to restore immune-system balance in conditions associated with excessive or dysregulated inflammation. The company is based in Israel and trades on the Nasdaq under the symbol ENLV.

Enlivex’s lead product candidate is Allocetra, an investigational, off-the-shelf cell therapy intended to reprogram immune cells known as macrophages and promote immune homeostasis. The therapy is being studied as a potential treatment for severe inflammatory conditions, including sepsis and osteoarthritis of the knee.

The company’s clinical development activities have included studies in Israel and other locations, with programs focused on evaluating Allocetra’s safety and potential efficacy.